Insulet EVOLUTION 2 trial reports 68% time in range for fully closed-loop insulin delivery in type 2 diabetes

Reuters

Mar 12

Insulet EVOLUTION 2 trial reports 68% time in range for fully closed-loop insulin delivery in type 2 diabetes

Insulet reported results from the EVOLUTION 2 multicenter feasibility study of its investigational fully closed-loop automated insulin delivery system for adults with type 2 diabetes, which were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. The study enrolled 24 adults in New Zealand aged 16–70 years with type 2 diabetes using insulin, and evaluated multiple algorithm versions. Using the final algorithm version with no boluses, participants achieved an average 68% time in range, representing a 24% improvement versus standard injection therapy. Time below range had a median of 0% below 70 mg/dL, and no severe hypoglycemia or diabetic ketoacidosis events were observed. Insulet said it plans to start the EVOLVE pivotal study in 2026 to support a 510(k) filing in 2027 and a commercial launch in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111601BIZWIRE_USPR_____20260311_BW660681) on March 11, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2618973357"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618973357\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618973357?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 04:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618973357","market":"fut","top_or_hot":-1,"title":"Insulet EVOLUTION 2 trial reports 68% time in range for fully closed-loop insulin delivery in type 2 diabetes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insulet EVOLUTION 2 trial reports 68% time in range for fully closed-loop insulin delivery in type 2 diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Insulet reported results from the EVOLUTION 2 multicenter feasibility study of its investigational fully closed-loop automated insulin delivery system for adults with type 2 diabetes, which were presented at the 19th International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD) in Barcelona. The study enrolled 24 adults in <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a> aged 16–70 years with type 2 diabetes using insulin, and evaluated multiple algorithm versions. Using the final algorithm version with no boluses, participants achieved an average 68% time in range, representing a 24% improvement versus standard injection therapy. Time below range had a median of 0% below 70 mg/dL, and no severe hypoglycemia or diabetic ketoacidosis events were observed. Insulet said it plans to start the EVOLVE pivotal study in 2026 to support a 510(k) filing in 2027 and a commercial launch in 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111601BIZWIRE_USPR_____20260311_BW660681) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insulet EVOLUTION 2 trial reports 68% time in range for fully closed-loop insulin delivery in type 2 diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsulet EVOLUTION 2 trial reports 68% time in range for fully closed-loop insulin delivery in type 2 diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 04:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Insulet EVOLUTION 2 trial reports 68% time in range for fully closed-loop insulin delivery in type 2 diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Insulet reported results from the EVOLUTION 2 multicenter feasibility study of its investigational fully closed-loop automated insulin delivery system for adults with type 2 diabetes, which were presented at the 19th International Conference on Advanced Technologies &amp; Treatments for Diabetes (ATTD) in Barcelona. The study enrolled 24 adults in <a href=\"https://laohu8.com/S/NZERF\">New Zealand</a> aged 16–70 years with type 2 diabetes using insulin, and evaluated multiple algorithm versions. Using the final algorithm version with no boluses, participants achieved an average 68% time in range, representing a 24% improvement versus standard injection therapy. Time below range had a median of 0% below 70 mg/dL, and no severe hypoglycemia or diabetic ketoacidosis events were observed. Insulet said it plans to start the EVOLVE pivotal study in 2026 to support a 510(k) filing in 2027 and a commercial launch in 2028.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111601BIZWIRE_USPR_____20260311_BW660681) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL3r8Bvt:1","article_id":"2618973357","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618973357","pubTimestamp":1773259285,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Insulet reported results from the EVOLUTION 2 multicenter feasibility study of its investigational fully closed-loop automated insulin delivery system for adults with type 2 diabetes, which were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes  in Barcelona. The study enrolled 24 adults in New Zealand aged 16–70 years with type 2 diabetes using insulin, and evaluated multiple algorithm versions. Using the final algorithm version with no boluses, participants achieved an average 68% time in range, representing a 24% improvement versus standard injection therapy. Time below range had a median of 0% below 70 mg/dL, and no severe hypoglycemia or diabetic ketoacidosis events were observed. Insulet said it plans to start the EVOLVE pivotal study in 2026 to support a 510 filing in 2027 and a commercial launch in 2028.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU1119994496.HKD":"FIDELITY WORLD \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","BK4551":"寇图资本持仓","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4566":"资本集团","BK4082":"医疗保健设备","PODD":"银休特","LU1084165304.USD":"FIDELITY WORLD \"A\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC"},"translate_title":"Insulet EVOLUTION 2试验报告2型糖尿病全闭环胰岛素输送的时间范围为68%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PODD":0.9},"content_text":"Insulet EVOLUTION 2 trial reports 68% time in range for fully closed-loop insulin delivery in type 2 diabetes\n    \n\n        Insulet reported results from the EVOLUTION 2 multicenter feasibility study of its investigational fully closed-loop automated insulin delivery system for adults with type 2 diabetes, which were presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. The study enrolled 24 adults in New Zealand aged 16–70 years with type 2 diabetes using insulin, and evaluated multiple algorithm versions. Using the final algorithm version with no boluses, participants achieved an average 68% time in range, representing a 24% improvement versus standard injection therapy. Time below range had a median of 0% below 70 mg/dL, and no severe hypoglycemia or diabetic ketoacidosis events were observed. Insulet said it plans to start the EVOLVE pivotal study in 2026 to support a 510(k) filing in 2027 and a commercial launch in 2028.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111601BIZWIRE_USPR_____20260311_BW660681) on March 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}